Chris Frew

LumaCyte Unveils Predictive CAR T Donor Analytics to Revolutionize Cell Therapy Manufacturing CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--LumaCyte, a leader in advanced cellular analysis and precision bioanalytics, proudly announces the launch of its groundbreaking cell therapy application for predictive CAR T donor analytics. Leveraging its novel Laser Force Cytology™ (LFC™) technology and Radiance® instrument, LumaCyte uncovers deep data insights into highly variable and complex patient and donor cellular starting material, enabling cell therapy developers to predict manufacturing success for specific donors or patients. To ensure that all interested partners can benefit from this powerful new application, LumaCyte has introduced a new donor qualification service where customers can ship donor or patient samples to LumaCyte for analysis and qualification. This service aims to revolutionize the cell therapy landscape by minimizing manufacturing risks due to variability in cellular starting material, enhancing production consistency, and increasing production yields. The industry has long sought to understand the innate variability across donors and patients and how to predict manufacturing and clinical success based on biomarkers in the cellular starting material. The ability to predict the outcome prior to the start of manufacturing with near real-time analytical insights is considered the holy grail for donor selection. Combining advanced in-process analytics with the ability to enable adaptive manufacturing would be a quantum leap for the immunotherapy industry; Reducing manufacturing failures and compressing time and costs for delivering these lifesaving treatments. “The biopharmaceutical industry is advancing scientific breakthroughs into the clinic faster than any other time in its history. Developers must think differently from the start to be able to meet the clinical and commercial manufacturing scale required to serve the hundreds of thousands of advanced therapy patients expected by 2030. “We are honored to do our part in providing valuable real-time data insights that have the power to accelerate the time to patient as well as improve the cost and effectiveness of these lifesaving treatments,” says Dr. Sean Hart, LumaCyte CEO and CSO. https://lnkd.in/eQvfBi4E

9

The world of LDTs is changing. If you're curious what that means for labs, check out this MedTech Dive article. https://lnkd.in/gYPuzuWa

2

📣 Join Our Roundtable Discussion on the Challenges Facing Drug Substance CDMOs in the Oligonucleotide Space! - Oligonucleotide Therapeutics Xchange, Maryland 2024. COMPLIMENTARY REGISTRATION: https://lnkd.in/ecsNKMQD Are you ready to dive into the critical challenges and opportunities within the Oligonucleotide space? Don't miss this exclusive roundtable discussion featuring key industry expert Trishul Shah, Director of Business Development and Head of Sales North America at PolyPeptide Group Discussion Topics: 📙 Timeline and Scale Expectations: Understand the critical timelines and scaling challenges in the current market. 📙 Selecting Your CMO: Learn what factors are most crucial when choosing your Contract Manufacturing Organization. 📙 Innovation and Greener Processes: Explore the importance of innovation and the shift towards more sustainable and environmentally-friendly processes. 🗣️ Trishul brings a wealth of knowledge and experience to the table, with his involvement in industry peer groups like the TIDES Advisory Committee and the Boulder Peptide Symposium Scientific Board. As a member of PolyPeptide Group’s Executive Strategic Team in the US and the Global team, Trishul offers invaluable insights into the evolving landscape of oligonucleotide therapeutics. 📅 Wednesday, 30 October, 2024 🕒 11:25 - 12:25 📍 Marriott Hotel, Maryland 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #OligonucleotideTherapeutics #CDMO #Biotech #Pharma #Innovation #Sustainability #PolyPeptideGroup #TIDES #BoulderPeptideSymposium #IndustryExpert #RoundtableDiscussion #DrugDevelopment #LifeSciences #Pharmaceuticals #Biopharma #GreenChemistry #Manufacturing #Therapeutics #Biotechnology #PharmaceuticalIndustry #ClinicalResearch #PharmaManufacturing #HealthTech #DrugSubstance #CMOSelection #GreenProcesses #IndustryEvent #Maryland2024 #BusinessDevelopment #PeerGroupDiscussion #ResearchAndDevelopment #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

59

🎯 Start Your Day at the Antibody Therapeutics Xchange with Rachel Fong! 🎯 We're excited to kick off the Antibody Therapeutics Xchange - Maryland 2024 with an insightful Opening Address & Keynote Presentation by Rachel Fong, Director of Strategic Partnerships at Integral Molecular. 🌟 ✨ REGISTER NOW and get your Complimentary Pass! https://lnkd.in/eqvCJ5MG 📅 Date: Monday, 28 October 2024 ⏰ Time: 08:30 AM - 09:00 AM 📍 Location: Marriott College Park, Maryland 💡 What to Expect: 🔬 Learn how cell-based protein arrays like the Membrane Proteome Array (MPA) are transforming antibody specificity testing. ⚙️ Understand the impact of off-target binding and how it contributes to drug attrition and patient risks. 🧪 Rachel Fong with over 10 years at Integral Molecular, has been a key player in launching the MPA platform and managing high-impact collaborations. As a co-author of over a dozen publications, she brings an expert perspective on guiding projects from concept to success. Don't miss this chance to dive deep into cutting-edge solutions that are shaping the future of antibody-based therapies! 🌍🔗 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #AntibodyTherapeutics #Biotech #Pharma #DrugDevelopment #AntibodyEngineering #Polyspecificity #IntegralMolecular #MembraneProteomeArray #AntibodySpecificity #TherapeuticInnovation #PharmaceuticalResearch #Biopharma #AntibodyDiscovery #MPATechnology #BiotechnologyEvent #TherapeuticDevelopment #ClinicalResearch #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

8

Do you know when companion diagnostics (CDx) are needed for your cell and gene therapy programs? Or what kind of testing is required and how to choose the right lab partner for a CDx assay? In our blog, you’ll learn from Labcorp subject matter experts as they answer key questions you may have about developing CDx for your cell and gene therapy programs. Learn more: https://lnkd.in/gSChJieM #CellandGeneTherapy #CompanionDiagnostics

4

🚀 Join us at the Antibody Therapeutics Xchange - Maryland 2024! 🔬💡 We're excited to highlight Birthe Jessen-Park, Technical Sales Specialist Custom Antibodies at Bio-Rad Laboratories🌟, an industry leader in antibody discovery, who will be presenting at two exciting sessions during this year's event: 📅 Time: 11:20 AM - 12:20 PM ✨ Roundtable Discussion: "The Perfect Workflow for Generating Antibody Drug Candidates" 🧬 Key topics covered include: 🤔 How many hits (binders) should be further analyzed? 🎯 What are the most relevant selection criteria? 🧠 Solving challenges like affinity, developability, and epitope selection. 📅 Time: 3:35 PM - 4:05 PM 🔍 Poster Presentation: "Rapid Generation of Bispecific Antibodies for High Throughput Screening with SpyLock Technology" 🧫 Birthe will introduce SpyLock Technology 🛠️, an innovative approach for creating bispecific antibodies. This technology, compatible with Bio-Rad’s Pioneer™ Antibody Discovery Platform, offers a faster, more efficient path to discovering bispecifics 🔝. With a rich background at Bio-Rad Laboratories, Alloy Therapeutics, and Medimmune, and a PhD from the University of Freiburg 🎓, Birthe brings unparalleled expertise to these sessions. 📍 Location: College Park Marriott, Maryland 🏨 📅 Date: October 28, 2024 Secure your spot and get your complimentary pass! https://lnkd.in/eqyZAeXX 💬 Don't miss this chance to connect with Birthe and other top industry experts! Let's shape the future of antibody therapeutics together! 💼✨ 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. #AntibodyTherapeutics #Biopharma #Biotechnology #PharmaInnovation #AntibodyDiscovery #DrugDevelopment #LeadOptimization #BioRad #TherapeuticsXchange #ADC #MultispecificAntibodies #BiopharmaLeaders #ProteinEngineering #BiotechEvents #PharmaIndustry #LifeSciences #TherapeuticInnovation #BiotechNetworking #ScientificResearch #AntibodyEngineering #PharmaCollaboration #NextGenTherapeutics #BioPharmaExperts #PharmaRND #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

4

🚀 Registration Now Open for the Oligonucleotide Therapeutics Xchange - Maryland 2024! 🚀 We are thrilled to share that registration is now open for hubXchange's Oligonucleotide Therapeutics Xchange Maryland 2024! This event will convene leading executives from the pharma and biotech sectors to tackle and find solutions for the critical challenges in Oligonucleotide Therapeutics. 📅 Date: Wednesday, October 30, 2024 🕗 Time: 8:00 AM - 6:15 PM 📍 Location: Maryland Join us to stay at the forefront of Oligonucleotide Therapeutics innovation and connect with fellow industry leaders. Don’t miss out—register today and get your Complimentary Pass! https://lnkd.in/eyChA_wt 🔎 Why Attend hubXchange? Take advantage of a unique platform that promotes knowledge exchange and industry connections. 🗣🔬 Featuring Industry Experts: Weiguo Zhai, Senior Director, R&D Analytical Sciences, BioPharmaceutical Development, AstraZeneca Xiaoyong Lu, M.S. Ph.D., Director of Oligonucleotide and Genetic Medicine, Eli Lilly and Company Antonio DiGiandomenico, Senior Director, AstraZeneca Jimmy Weterings, VP, Research RNA Therapeutics & Delivery, Sirnaomics Jeremy Little, Director of Custom Oligonucleotides, ChemGenes Trishul Shah, Director Business Development, Head of Sales North America, PolyPeptide Group Jeremy Little, Director of Custom Oligonucleotides, ChemGenes David Brown, Director, RNAimmune David Blackmon, Director, Alcyone Therapeutics Inc. Our Partners: 🤝 ChemGenes 🤝 PolyPeptide Group 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #OligonucleotideTherapeutics #Pharma #Biotech #hubXchange #Networking #Innovation #MarylandEvent #DrugDevelopment #RNAtherapeutics #GeneticMedicine #Biopharma #Pharmaceuticals #Biotechnology #LifeSciences #MedicalResearch #HealthcareInnovation #BiotechCommunity #ScientificConference #Therapeutics #BiotechInnovation #PharmaConference #ClinicalResearch #DrugDelivery #NewModalities #OligonucleotideDiscovery #PharmaNetworking #PharmaEvents #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

6

Ursheet P. from Mayfield Fund message to early founders: Don’t try to do it all on your own. You can get to scale faster, cheaper, and more efficiently through partnerships, collaborations, and outsourcing. Focus on your core capabilities and look externally to execute on scalability. #synbiobeta2024

12

Regenerative therapy is the future of medicine that holds the promise for an end to many chronic debilitating diseases and the increase of health span in humans and animals. SMSbiotech is introducing an accessible and affordable approach to regenerative therapy using their unique and novel stem cells….

2

#BigPharma's growing interest in the #cellandgenetherapy space has the potential to reshape the industry's future. At this year's Cell & Gene #MeetingontheMesa, industry leaders highlighted that large pharma companies' significant resources and expertise are uniquely positioned to address the complex challenges of developing and commercializing these therapies. From high #manufacturing costs to navigating #regulatory hurdles, Big Pharma is playing an essential role in scaling innovations that smaller biotechs often struggle to bring to market. Their partnerships will prove critical to bringing life saving treatments to patients who need them most. As the sector continues to evolve, collaboration between Big Pharma and biotech can help shape the future of cell and gene therapies.

49

1 Comment

Kevin King, BioIVT’s Senior Director of #Donor Center Strategy and Growth will be providing his industry insight and expertise by moderating a roundtable session at the 2nd Annual Donor Selection & Source Summit today entitled “Mitigating Risks in #CellandGeneTherapy: Re-evaluating Donor Selection and Characterizing Cellular Starting Material". The discussion will include topics like: • Establishing industry standard criteria for donor eligibility and implementation of advanced screening technologies. • Characterization of cellular properties and standardized assays to assess donor derived cell quality and function. As experts in providing RUO & GMP cellular starting and ancillary materials for the manufacture of #AdvancedTherapies, our aim is to foster collaboration between stakeholders to share needs as well as provide input on implementing risk mitigation strategies and foresight for sourcing donor-derived cellular starting material. Make sure to connect with Kevin and Lisa Kretzschmar, MBA if you will be at the event. If you are not attending the event, you can contact our experts here: https://hubs.ly/Q02Ywbkk0 Or view a recording of one of our previous expert roundtables here: https://hubs.ly/Q02Yw96w0 And access other insightful reference materials here: https://hubs.ly/Q02Ywf510) #CellTherapy #GeneTherapy #ATMPs

19

🚨 Webinar Announcement: Improving Outcomes and Access to Precision Medicine🚨- https://lnkd.in/eSvkPZPG Despite groundbreaking advances in precision medicine, a critical gap remains: the lack of diverse representation in genomic data, leading to unequal healthcare outcomes—especially for people of color. 🔬 What is the impact? Genomic testing is a cornerstone of modern medicine, yet current databases are largely based on data from individuals of European descent. This leaves underrepresented populations at a disadvantage, with less effective treatments and limited access to life-saving innovations. 💡What you’ll learn: 1️⃣ Understanding the genomic testing gap and the structural barriers in healthcare 2️⃣ How to advance precision medicine for all, ensuring inclusivity 3️⃣ Practical strategies for improving access, including policy changes, community engagement, and innovative healthcare models 📅 Date: Thursday, 21st November, 2024 ⏰ Time: 12:00pm - 1:00pm ET 📍 Location: Zoom (Register Here https://lnkd.in/eSvkPZPG) Let’s work together to create a healthcare system that serves everyone. #PrecisionMedicine #GenomicTesting #HealthEquity

15

1 Comment

Discover Silo's research in development through collaboration with the University of Maryland. SPU-16 targets #multiplesclerosis, the most common neurological disorder among young adults. Learn more about our drug here: https://bit.ly/40vPhAN #Science #Biotech #Biotechnology #Biopharma #MultipleSclerosis

3

BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell - https://lnkd.in/eUv2kfKq Brightpath Biotherapeutics (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic’s innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the durability of clinical responses. However, achieving clinical- scale manufacturing of such a rare subset of T cells while preserving their original functionality has conventionally been a significant challenge. Induced pluripotent stem (iPS) cell technology has overcome this barrier, making large-scale production feasible.“ stated Ken Nagai, CEO of BrightPath. “We are excited to partner with BrightPath in the development of their revolutionary iPSC-derived cell therapy,” said Gustavo Mahler, CEO of Cellistic. “Our Echo manufacturing platform is designed to meet the unique challenges of cell therapy production, ensuring scalability, quality, and regulatory compliance. Together, we can advance the therapeutic potential of BCMA CAR-NKT cells and help BrightPath to bring innovative solutions to patients in need.” #ipscells #tcells #advancedtherapies Laetitia Avanzini

35

A Curative Solution: How Cell & Gene Therapies Support Patients & NJ’s Life Sciences Industry https://ow.ly/xOPe50UnvNc #CellTherapy #GeneTherapy #LifeSciences #Biotech #HealthcareInnovation #PatientCare #NewJerseyLifeSciences

2

Our latest blog dives into the importance of cell density, even distribution and the science behind effective seeding techniques. Learn how understanding these steps can lead to more precise evaluations of cellular reactivity. https://lnkd.in/gYhukzVr blog&utm_term=&utm_marketing_tactic=aw #CellCulture #Cytotoxicity #CellSeeding

3

Jonathan Montagu, CEO of MassBio member HotSpot Therapeutics, Inc., writes on the #LifeSCiVC blog about hopes around an immuno-oncology spring this year, aligning with the emergence of #biotech from its own long winter. Jonathan points out that after the #lifesciences industry dove headfirst into I-O “to address the substantial need that still persists for many cancer patients with a range of tumor types,” much of the second-generation agents fell short. He writes about why he’s optimistic that new approaches have started to turn the tide. What are your thoughts on the I-O space right now? https://lnkd.in/eMh62Z8j #immunooncology #oncology #patientdriven

28